Vir Biotechnology, Inc. (NASDAQ:VIR – Get Free Report) has received a consensus rating of “Moderate Buy” from the seven brokerages that are covering the firm, MarketBeat reports. Three investment analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price objective among brokerages […]